Intradermal Hepatitis-B-vaccination in non-responders after application of imiquimod 5% at the site of vaccination.

Intradermal Hepatitis-B-vaccination in non-responders after topical application of imiquimod 5%.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON24074

Enrollment

Registered

2007-08-31

Start date

2007-05-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-responsiveness to hepatitis B vaccination (with recombinant vaccine).

Interventions

Intradermal hepatitis B vaccination with recombinant vaccine after topical treatment with imiquimod 5% cream

Eligibility

Inclusion criteria

Inclusion criteria: 1. >18 yrs; 2. Minimal 2 series of Hepatitis B vaccination (= minimal 6 intramuscular injections of 10microgr recombinant hepatitis B vaccine) with antibody titre <10IU/ml.

Exclusion criteria

Exclusion criteria: 1. Carrier of hepatitis B virus; 2. Known immunosuppressive state due to illness or medication; 3. Autoimmune disorder; 4. Pregnancy.

Design outcomes

Primary

Measure	Time frame
Serologic response after vaccination	—

Secondary

Measure	Time frame
Adverse events Cellular immunity	—

Contacts

Public ContactA.H.E. Roukens

Leiden University Medical Center (LUMC), P.O. Box 9600

a.h.e.roukens@lumc.nl

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)